Tissue inhibitor of metalloproteinase-4 is elevated in early-stage breast cancers with accelerated progression and poor clinical course.
An increasing number of breast cancer patients are diagnosed with small, localized, early-stage tumors. These patients are typically thought to have a good prognosis for long-term disease-free survival, but epidemiological studies indicate that up to 30% may have a recurrence within 3 to 5 years of diagnosis. Identifying patients with a high risk of recurrence and/or progression is important because they could be more aggressively treated at diagnosis to improve their chances for disease-free survival. Recent evidence suggests that elevated levels of the matrix metalloproteinase inhibitor, tissue inhibitor of metalloproteinase (TIMP)-4, are associated with malignant progression of ductal carcinoma in situ, a precancerous lesion. To examine the association of TIMP-4 with survival outcomes, we conducted a retrospective immunohistochemical analysis of 314 cases from patients with early-stage disease, defined as tumors smaller than 2 cm and no spread to lymph nodes (tumor-node-metastasis staging: T1N0MX). We found that tumors with elevated levels of TIMP-4 were correlated with a reduced probability of long-term disease-free survival, especially in patients with estrogen receptor-negative tumors. Our findings prompt further evaluation of TIMP-4 as a simple prognostic marker that may help identify patients with early-stage breast cancer who could benefit from more aggressive treatment at diagnosis.
Liss
Michaelann
M
Department of Hematology/Oncology, Lankenau Hospital, 100 Lancaster Ave., Wynnewood, PA 19096, USA.
Sreedhar
Nandhini
N
Keshgegian
Albert
A
Sauter
Guido
G
Chernick
Michael R
MR
Prendergast
George C
GC
Wallon
U Margaretha
UM
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000378:metabolism / Q000473:pathology; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D011960:Receptors, Estrogen / Q000378:metabolism; D012189:Retrospective Studies; D019714:Tissue Inhibitor of Metalloproteinases / Q000096:biosynthesis*; D000097792:Tissue Inhibitor of Metalloproteinase-4
D014408:Biomarkers, Tumor; D011960:Receptors, Estrogen; D019714:Tissue Inhibitor of Metalloproteinases; D000097792:Tissue Inhibitor of Metalloproteinase-4
J Biol Chem. 2000 Dec 29;275(52):41358-63
11007798
Histopathology. 2008 Jan;52(1):108-18
18171422
Nat Med. 2003 Apr;9(4):407-15
12652295
Cancer. 1999 Oct 1;86(7):1263-72
10506713
Br J Cancer. 2003 Nov 17;89(10):1817-21
14612884
Breast Cancer Res Treat. 2003 Mar;78(1):105-18
12611463
J Natl Cancer Inst. 1992 Jul 1;84(13):1017-22
1318976
Cancer Res. 2005 Feb 1;65(3):898-906
15705888
J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):375-92
12013528
Oncogene. 1997 Jun 12;14(23):2767-74
9190892
Eur J Cell Biol. 1997 Oct;74(2):111-22
9352216
Mod Pathol. 1998 Feb;11(2):155-68
9504686
Dev Biol. 1999 Jul 15;211(2):238-54
10395785
Annu Rev Cell Dev Biol. 2001;17:463-516
11687497
Int J Cancer. 2007 Aug 15;121(4):714-23
17455256
Clin Cancer Res. 2004 Apr 1;10(7):2289-98
15073104
Crit Rev Oncol Hematol. 2004 Mar;49(3):187-98
15036259
Lancet Oncol. 2007 Mar;8(3):235-44
17329194
Clin Cancer Res. 2006 Dec 1;12(23):7054-8
17114213
Biochim Biophys Acta. 2000 Mar 7;1477(1-2):267-83
10708863
BMC Cancer. 2008 Nov 07;8:323
18990247
J Cell Physiol. 1993 Nov;157(2):351-8
7693724
Pharmacol Ther. 1993 Sep;59(3):329-41
8309995
Cancer Res. 1994 Sep 1;54(17):4791-7
8062280
Cancer Res. 2001 Mar 15;61(6):2365-70
11289097
Cancer Res. 2004 Jan 15;64(2):590-8
14744773